Several candidate drugs have been identified.<h4>Conclusion</h4><i>FCRLA, GREM1</i>, and <i>MMP9</i> are inflammation-associated genes that may link the pathobiology of COPD and LUAD, and serve as valuable biomarkers with therapeutic potential in high-risk populations. This evidence concerns the gene GREM1 and chronic obstructive pulmonary disease.